These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35231399)

  • 1. Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo.
    Georgiev GI; Malonis RJ; Wirchnianski AS; Wessel AW; Jung HS; Cahill SM; Nyakatura EK; Vergnolle O; Dowd KA; Cowburn D; Pierson TC; Diamond MS; Lai JR
    Cell Chem Biol; 2022 May; 29(5):811-823.e7. PubMed ID: 35231399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    Frei JC; Wirchnianski AS; Govero J; Vergnolle O; Dowd KA; Pierson TC; Kielian M; Girvin ME; Diamond MS; Lai JR
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge.
    De Lorenzo G; Tandavanitj R; Doig J; Setthapramote C; Poggianella M; Sanchez-Velazquez R; Scales HE; Edgar JM; Kohl A; Brewer J; Burrone OR; Patel AH
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33028720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.
    Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM
    J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Zika Virus Envelope Protein Domain III as a Target of Human Neutralizing Antibodies.
    Gallichotte EN; Young EF; Baric TJ; Yount BL; Metz SW; Begley MC; de Silva AM; Baric RS
    mBio; 2019 Sep; 10(5):. PubMed ID: 31530669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy.
    Tai W; Chen J; Zhao G; Geng Q; He L; Chen Y; Zhou Y; Li F; Du L
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dengue virus envelope protein domain III-elicited antibodies mediate cross-protection against Zika virus in a mouse model.
    Zhou Y; Chen D; Yang L; Zou W; Duan Z; Zhang Y; Wen J
    Virus Res; 2020 Mar; 278():197882. PubMed ID: 31981774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies.
    Contreras M; Stuart JB; Levoir LM; Belmont L; Goo L
    mBio; 2024 Feb; 15(2):e0304823. PubMed ID: 38193697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yeast-produced subunit protein vaccine elicits broadly neutralizing antibodies that protect mice against Zika virus lethal infection.
    Zhang W; Qu P; Li D; Zhang C; Liu Q; Zou G; Dupont-Rouzeyrol M; Lavillette D; Jin X; Yin F; Huang Z
    Antiviral Res; 2019 Oct; 170():104578. PubMed ID: 31394119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-dose circular RNA vaccine prevents Zika virus infection without enhancing dengue severity in mice.
    Liu X; Li Z; Li X; Wu W; Jiang H; Zheng Y; Zhou J; Ye X; Lu J; Wang W; Yu L; Li Y; Qu L; Wang J; Li F; Chen L; Wu L; Feng L
    Nat Commun; 2024 Oct; 15(1):8932. PubMed ID: 39414822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement.
    Shukla R; Shanmugam RK; Ramasamy V; Arora U; Batra G; Acklin JA; Krammer F; Lim JK; Swaminathan S; Khanna N
    EBioMedicine; 2020 Apr; 54():102738. PubMed ID: 32305868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor.
    Dussupt V; Sankhala RS; Gromowski GD; Donofrio G; De La Barrera RA; Larocca RA; Zaky W; Mendez-Rivera L; Choe M; Davidson E; McCracken MK; Brien JD; Abbink P; Bai H; Bryan AL; Bias CH; Berry IM; Botero N; Cook T; Doria-Rose NA; Escuer AGI; Frimpong JA; Geretz A; Hernandez M; Hollidge BS; Jian N; Kabra K; Leggat DJ; Liu J; Pinto AK; Rutvisuttinunt W; Setliff I; Tran U; Townsley S; Doranz BJ; Rolland M; McDermott AB; Georgiev IS; Thomas R; Robb ML; Eckels KH; Barranco E; Koren M; Smith DR; Jarman RG; George SL; Stephenson KE; Barouch DH; Modjarrad K; Michael NL; Joyce MG; Krebs SJ
    Nat Med; 2020 Feb; 26(2):228-235. PubMed ID: 32015557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mimotope discovery as a tool to design a vaccine against Zika and dengue viruses.
    Cuevas-Juárez E; Liñan-Torres A; Hernández C; Kopylov M; Potter CS; Carragher B; Ramírez OT; Palomares LA
    Biotechnol Bioeng; 2023 Sep; 120(9):2658-2671. PubMed ID: 37058415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice.
    Yang M; Lai H; Sun H; Chen Q
    Sci Rep; 2017 Aug; 7(1):7679. PubMed ID: 28794424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection.
    Slon-Campos JL; Dejnirattisai W; Jagger BW; López-Camacho C; Wongwiwat W; Durnell LA; Winkler ES; Chen RE; Reyes-Sandoval A; Rey FA; Diamond MS; Mongkolsapaya J; Screaton GR
    Nat Immunol; 2019 Oct; 20(10):1291-1298. PubMed ID: 31477918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cross-reactive dengue virus-derived monoclonal antibodies to Zika virus envelope protein: Panacea or Pandora's box?
    Gunawardana SA; Shaw RH
    BMC Infect Dis; 2018 Dec; 18(1):641. PubMed ID: 30526531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.